A New Frontier in the Co-Management of Thyroid Eye Disease: Recent Episodes
Annenberg Center for Health Sciences
Thyroid eye disease, also known as Graves’ orbitopathy, is a potentially serious, progressive autoimmune disease that most often occurs in people with hyperthyroidism, ie, Graves’ disease. Kimberley Cockerham, MD, FACS, moderates this series of six, paired conversations between endocrinologist Terry J. Smith, MD, and eye specialists Wendy W. Lee, MD, and Raymond Douglas, MD, PhD, to explore current and emerging treatment options for thyroid eye disease. In these conversations, faculty review the current understanding of the burden and pathophysiology of thyroid eye disease—including treatment
- The role for external beam radiation and orbital decompression in treating patients with thyroid eye disease
- Other surgical options for treating patients with thyroid eye disease
- Clinical data supporting the approval of teprotumumab
- How efficacy was assessed in the teprotumumab trials
- Emerging therapies for patients with thyroid eye disease
- The role of intervention in patient management
- Therapy selection for patients with thyroid eye disease
- Evaluating treatment responses
- How patients present with thyroid eye disease
- Differential diagnosis for thyroid eye disease
- How endocrinologists and ophthalmologists approach patient evaluation
- Incidence and prevalence of thyroid eye disease
- The clinical implications of thyroid eye disease for patients
- The traditional course of thyroid eye disease